Year |
Citation |
Score |
2024 |
Rodriguez-Vieitez E, Kumar A, Malarte ML, Ioannou K, Rocha FM, Chiotis K. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. Methods in Molecular Biology (Clifton, N.J.). 2785: 195-218. PMID 38427196 DOI: 10.1007/978-1-0716-3774-6_13 |
0.582 |
|
2023 |
Chiotis K, Johansson C, Rodriguez-Vieitez E, Ashton NJ, Blennow K, Zetterberg H, Graff C, Nordberg A. Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer's disease with multi-modal PET and plasma GFAP. Molecular Neurodegeneration. 18: 60. PMID 37697307 DOI: 10.1186/s13024-023-00647-y |
0.555 |
|
2023 |
Bucci M, Bluma M, Savitcheva I, Ashton NJ, Chiotis K, Matton A, Kivipelto M, Di Molfetta G, Blennow K, Zetterberg H, Nordberg A. Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic. Translational Psychiatry. 13: 268. PMID 37491358 DOI: 10.1038/s41398-023-02558-4 |
0.609 |
|
2023 |
Fontana IC, Scarpa M, Malarte ML, Rocha FM, Ausellé-Bosch S, Bluma M, Bucci M, Chiotis K, Kumar A, Nordberg A. Astrocyte Signature in Alzheimer's Disease Continuum through a Multi-PET Tracer Imaging Perspective. Cells. 12. PMID 37296589 DOI: 10.3390/cells12111469 |
0.664 |
|
2023 |
Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring-Matton A, Ashton NJ, Molfetta GD, Grötschel L, Kivipelto M, Blennow K, Zetterberg H, Savitcheva I, Nordberg A, Otto M. Blood β-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37052206 DOI: 10.1002/alz.13046 |
0.496 |
|
2021 |
Bucci M, Chiotis K, Nordberg A. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Molecular Psychiatry. PMID 34593971 DOI: 10.1038/s41380-021-01263-2 |
0.644 |
|
2021 |
Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, Bischof GN, Chiotis K, Leuzy A, Wolters EE, Walter M, Rabinovici GD, Carrillo M, Drzezga A, Hansson O, et al. Correction to: The Strategic Biomarker Roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging. PMID 34546388 DOI: 10.1007/s00259-021-05549-z |
0.467 |
|
2021 |
Colato E, Chiotis K, Ferreira D, Mazrina MS, Lemoine L, Mohanty R, Westman E, Nordberg A, Rodriguez-Vieitez E. Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 34511502 DOI: 10.3233/JAD-210614 |
0.705 |
|
2021 |
Chiotis K, Dodich A, Boccardi M, Festari C, Drzezga A, Hansson O, Ossenkoppele R, Frisoni G, Garibotto V, Nordberg A. Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging. PMID 33723628 DOI: 10.1007/s00259-021-05277-4 |
0.601 |
|
2021 |
Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, Bischof GN, Chiotis K, Leuzy A, Wolters EE, Walter MA, Rabinovici GD, Carrillo M, Drzezga A, Hansson O, et al. The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging. PMID 33688996 DOI: 10.1007/s00259-020-05120-2 |
0.514 |
|
2020 |
Mohanty R, Mårtensson G, Poulakis K, Muehlboeck JS, Rodriguez-Vieitez E, Chiotis K, Grothe MJ, Nordberg A, Ferreira D, Westman E. Comparison of subtyping methods for neuroimaging studies in Alzheimer's disease: a call for harmonization. Brain Communications. 2: fcaa192. PMID 33305264 DOI: 10.1093/braincomms/fcaa192 |
0.526 |
|
2020 |
Smailovic U, Koenig T, Savitcheva I, Chiotis K, Nordberg A, Blennow K, Winblad B, Jelic V. Regional disconnection in Alzheimer dementia and amyloid positive MCI: Association of EEG functional connectivity and brain glucose metabolism. Brain Connectivity. PMID 33073602 DOI: 10.1089/brain.2020.0785 |
0.625 |
|
2020 |
Chiotis K, Savitcheva I, Poulakis K, Saint-Aubert L, Wall A, Antoni G, Nordberg A. [F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease. Molecular Psychiatry. PMID 32616831 DOI: 10.1038/S41380-020-0815-4 |
0.799 |
|
2019 |
Murugan NA, Chiotis K, Rodriguez-Vieitez E, Lemoine L, Ågren H, Nordberg A. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. European Journal of Nuclear Medicine and Molecular Imaging. PMID 30919054 DOI: 10.1007/S00259-019-04305-8 |
0.56 |
|
2019 |
Leuzy A, Savitcheva I, Chiotis K, Lilja J, Andersen P, Bogdanovic N, Jelic V, Nordberg A. Clinical impact of [F]flutemetamol PET among memory clinic patients with an unclear diagnosis. European Journal of Nuclear Medicine and Molecular Imaging. PMID 30915522 DOI: 10.1007/S00259-019-04297-5 |
0.652 |
|
2019 |
Jonasson M, Wall A, Chiotis K, Leuzy A, Eriksson J, Antoni G, Nordberg A, Lubberink M. Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [F]THK5317 PET. Neuroimage. Clinical. 22: 101681. PMID 30710871 DOI: 10.1016/J.Nicl.2019.101681 |
0.628 |
|
2019 |
Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Molecular Psychiatry. PMID 30635637 DOI: 10.1038/S41380-018-0342-8 |
0.765 |
|
2019 |
Leuzy A, Cicognola C, Chiotis K, Saint-Aubert L, Lemoine L, Andreasen N, Zetterberg H, Ye K, Blennow K, Höglund K, Nordberg A. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. PMID 30610252 DOI: 10.1007/S00259-018-4242-6 |
0.8 |
|
2019 |
Carter SF, Chiotis K, Nordberg A, Rodriguez-Vieitez E. Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. 46: 348-356. PMID 30515545 DOI: 10.1007/S00259-018-4217-7 |
0.781 |
|
2019 |
Lemoine L, Chiotis K, Leuzy A, Nennesmo I, Nordberg AK. P4‐599: Ante‐Mortem Binding Of 18F‐Thk5317 Pet In A Case Of Ftld And Post‐Mortem Comparison Of Tau Binding Using 3H‐Thk5117 And 3H‐Mk6240 Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.08.147 |
0.418 |
|
2018 |
Oliveira F, Leuzy A, Castelhano J, Chiotis K, Hasselbalch SG, Rinne J, Mendonça A, Otto M, Lleó A, Santana I, Johansson J, Anderl-Straub S, Arnim C, Beer A, Blesa R, et al. Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species. Neuroimage. Clinical. 20: 603-610. PMID 30186764 DOI: 10.1016/J.Nicl.2018.08.023 |
0.671 |
|
2018 |
Lilja J, Leuzy A, Chiotis K, Savitcheva I, Sörensen J, Nordberg A. Spatial normalization of [F]flutemetamol PET images utilizing an adaptive principal components template. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29903930 DOI: 10.2967/Jnumed.118.207811 |
0.612 |
|
2018 |
Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 232-236. PMID 29780868 DOI: 10.1016/J.Dadm.2018.01.007 |
0.641 |
|
2018 |
Chiotis K, Stenkrona P, Almkvist O, Stepanov V, Ferreira D, Arakawa R, Takano A, Westman E, Varrone A, Okamura N, Shimada H, Higuchi M, Halldin C, Nordberg A. Dual tracer tau PET imaging reveals different molecular targets for C-THK5351 and C-PBB3 in the Alzheimer brain. European Journal of Nuclear Medicine and Molecular Imaging. PMID 29752516 DOI: 10.1007/S00259-018-4012-5 |
0.749 |
|
2018 |
Mazrina MS, Chiotis K, Colato E, Nordberg AK, Rodriguez-Vieitez E, Initiative ADN. P4-308: Modelling The Associations Between [18F]Av1451, [18F]Fdg Pet And Cognition In Mild Cognitive Impairment And Ad Dementia Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.07.131 |
0.534 |
|
2018 |
Leuzy A, Lilja J, Heurling K, Chiotis K, Savitcheva I, Nordberg AK. Ic-P-016: Estimation Of Amyloid Load Using [18F]Flutemetamol And A Normalization Derived Weighting Factor: Potential Applications In Amyloid Pet Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2080 |
0.468 |
|
2017 |
Leuzy A, Rodriguez-Vieitez E, Saint-Aubert L, Chiotis K, Almkvist O, Savitcheva I, Jonasson M, Lubberink M, Wall A, Antoni G, Nordberg A. Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29268078 DOI: 10.1016/J.Jalz.2017.11.008 |
0.829 |
|
2017 |
Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR, Nobili F, Nordberg A, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. The Lancet. Neurology. 16: 661-676. PMID 28721928 DOI: 10.1016/S1474-4422(17)30159-X |
0.774 |
|
2017 |
Iaccarino L, Chiotis K, Alongi P, Almkvist O, Wall A, Cerami C, Bettinardi V, Gianolli L, Nordberg A, Perani D. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. Journal of Alzheimer's Disease : Jad. 59: 603-614. PMID 28671117 DOI: 10.3233/Jad-170158 |
0.79 |
|
2017 |
Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, Leuzy A, Almkvist O, Savitcheva I, Jonasson M, Lubberink M, Wall A, Antoni G, Nordberg A. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia. Molecular Psychiatry. 23: 1666-1673. PMID 28507319 DOI: 10.1038/Mp.2017.108 |
0.851 |
|
2017 |
Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, Garibotto V, Herholz K, Nobili F, Nordberg A. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging. 52: 214-227. PMID 28317650 DOI: 10.1016/J.Neurobiolaging.2016.07.012 |
0.818 |
|
2017 |
Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions. Molecular Neurodegeneration. 12: 19. PMID 28219440 DOI: 10.1186/S13024-017-0162-3 |
0.819 |
|
2017 |
Chiotis K, Stenkrona P, Almkvist O, Arakawa R, Takano A, Stepanov V, Varrone A, Higuchi M, Halldin C, Nordberg A. [IC-P-178]: HEAD-TO-HEAD IN VIVO
COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER's DISEASE: [11
C]THK5351 VERSUS [11
C]PBB3 PET IMAGING Alzheimer's & Dementia. 13: P133-P133. DOI: 10.1016/J.Jalz.2017.06.2553 |
0.761 |
|
2017 |
Leuzy A, Chiotis K, Jelic V, Andersen P, Friman J, Lilja J, Savitcheva I, Nordberg A. Investigating The Clinical Impact Of [18F]Flutemetamol Pet In A Tertiary Memory Clinic Setting In Patients With Uncertain Diagnosis Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.2288 |
0.573 |
|
2016 |
Saint-Aubert L, Almkvist O, Chiotis K, Almeida R, Wall A, Nordberg A. Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease. Alzheimer's Research & Therapy. 8: 38. PMID 27683159 DOI: 10.1186/S13195-016-0204-Z |
0.853 |
|
2016 |
Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonça A, Otto M, Lleó A, Castelo-Branco M, Santana I, Johansson J, Anderl-Straub S, von Arnim CA, Beer A, Blesa R, Fortea J, et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study. Brain : a Journal of Neurology. PMID 27401520 DOI: 10.1093/Brain/Aww160 |
0.563 |
|
2016 |
Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, Wall A, Nordberg A. Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer's disease. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. PMID 27107028 DOI: 10.1177/0271678X16645593 |
0.813 |
|
2016 |
Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M, Eriksson J, Lubberink M, Almkvist O, Wall A, Antoni G, Nordberg A. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. European Journal of Nuclear Medicine and Molecular Imaging. 43: 1686-99. PMID 26996778 DOI: 10.1007/S00259-016-3363-Z |
0.85 |
|
2016 |
Rodriguez-Vieitez E, Carter SF, Chiotis K, Saint-Aubert L, Leuzy A, Schöll M, Almkvist O, Wall A, Långström B, Nordberg A. Comparison of Early-Phase 11C-Deuterium-L-Deprenyl and 11C-PiB PET for Assessing Brain Perfusion in Alzheimer's Disease. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26912447 DOI: 10.2967/Jnumed.115.168732 |
0.798 |
|
2016 |
Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M, Chiotis K, Thordardottir S, Graff C, Wall A, Långström B, Nordberg A. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain : a Journal of Neurology. PMID 26813969 DOI: 10.1093/Brain/Awv404 |
0.807 |
|
2016 |
Jonasson M, Wall A, Chiotis K, Saint-Aubert L, Wilking H, Sprycha M, Borg B, Thibblin A, Eriksson JP, Sörensen J, Antoni G, Nordberg A, Lubberink M. Tracer kinetic analysis of (S)-18F-THK5117 as a PET tracer for assessing tau pathology. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26795290 DOI: 10.2967/Jnumed.115.158519 |
0.829 |
|
2016 |
Chiotis K, Saint-Aubert L, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau pet imaging in neurodegenerative tauopathies – a multimodal paradigm Neurobiology of Aging. 39. DOI: 10.1016/J.Neurobiolaging.2016.01.125 |
0.791 |
|
2016 |
Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, Nordberg A. Comparison of Early-Phase (S)-[18F]THK5117 and [11C]PIB PET imaging to assess brain perfusion in Alzheimer’s disease Neurobiology of Aging. 39. DOI: 10.1016/J.Neurobiolaging.2016.01.095 |
0.804 |
|
2016 |
Leuzy A, Chiotis K, Pannee J, Hasselbalch S, Rinne J, Castelo-Branco M, Mendonca A, Santana I, Bisa AL, Johansson J, Otto M, Portelius E, Zetterberg H, Blennow K, Nordberg A. Improved concordance between [11C]PIB PET and CSF Aβ42 using Aβ42/Aβ40: findings from a multicentre European memory clinic population Neurobiology of Aging. 39. DOI: 10.1016/J.Neurobiolaging.2016.01.084 |
0.604 |
|
2016 |
Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, Almkvist O, Wall A, Nordberg A. Early-Phase [11C]Pib Pet Is Comparable To [18F]Fdg Pet As A Marker Of Disease Progression In Alzheimer'S Disease Alzheimers & Dementia. 12: 1171. DOI: 10.1016/J.Jalz.2016.07.094 |
0.845 |
|
2016 |
Nordberg A, Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Almkvist O, Wall A, Antoni G. Longitudinal Changes In Regional Tau Deposition In Alzheimer'S Disease And Other Tauopathies Measured By [18F]-Tkh5317 Pet In A Multi-Tracer Design Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.645 |
0.837 |
|
2016 |
Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Wall A, Antoni G, Nordberg A. Tau Pet Imaging In Non-Alzheimer’S Disease Dementia: A Multimodal Paradigm Alzheimers & Dementia. 12: 137. DOI: 10.1016/J.Jalz.2016.06.1925 |
0.806 |
|
2016 |
Saint-Aubert L, Chiotis K, Wall A, Almkvist O, Nordberg A. P1-306: Association Between in Vivo TAU Deposition Measured Using [18F]THK5317 Pet and Cognitive Functions in Alzheimer's Disease Alzheimer's & Dementia. 12: P539-P540. DOI: 10.1016/J.Jalz.2016.06.1056 |
0.835 |
|
2016 |
Boccardi M, Yasui Y, Cerami C, Chiotis K, Garibotto V, Mattsson N, Sonni I, Kate Mt, Porteri C, Jack CR, Winblad B, Frisoni GB. Roadmap To The Biomarker-Based Diagnosis Of Alzheimer’S Disease Alzheimers & Dementia. 12: 13. DOI: 10.1016/J.Jalz.2016.06.012 |
0.343 |
|
2015 |
Chiotis K, Carter SF, Farid K, Savitcheva I, Nordberg A. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. European Journal of Nuclear Medicine and Molecular Imaging. 42: 1492-506. PMID 26130168 DOI: 10.1007/S00259-015-3115-5 |
0.777 |
|
2015 |
Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 45: 1077-88. PMID 25649653 DOI: 10.3233/Jad-142952 |
0.834 |
|
2015 |
Rodriguez-Vieitez E, Carter SF, Saint-Aubert L, Almkvist O, Farid K, Schöll M, Chiotis K, Thordardottir S, Wall A, Graff C, Långström B, Nordberg A. IC-P-126: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease Alzheimer's & Dementia. 11: P86-P86. DOI: 10.1016/J.Jalz.2015.06.148 |
0.805 |
|
2014 |
Chiotis K, Carter SF, Farid K, Nordberg A. IC-P-025: AGE IS A SIGNIFICANT FACTOR IN DETERMINING PATHOLOGICAL POSITIVITY MEASURED WITH [18F]FLORBETAPIR PET Alzheimer's & Dementia. 10: P18-P18. DOI: 10.1016/J.Jalz.2014.05.029 |
0.725 |
|
2013 |
Chiotis K, Carter S, Nordberg A. P1-320: Comparison of PiB-PET data to florbetapir-PET data acquired from cohorts at different research sites Alzheimer's & Dementia. 9: P275-P275. DOI: 10.1016/J.Jalz.2013.05.546 |
0.664 |
|
2013 |
Chiotis K, Carter S, Nordberg A. Comparison of PiB-PET data to florbetapir-PET data acquired from different patient cohorts at different research sites Alzheimers & Dementia. 9: 13. DOI: 10.1016/J.Jalz.2013.05.007 |
0.729 |
|
Show low-probability matches. |